Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 27, 2016. The document serves as a transaction notification regarding a sale of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the sale of 10,000 ordinary shares by Sir Andrew Witty, Chief Executive Officer.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a factual record of a transaction executed on the London Stock Exchange.
Key Facts for Investor Verification
- Transaction Type: Sale of 10,000 Ordinary Shares (25 pence each).
- Insider Involved: Sir Andrew Witty, Chief Executive Officer.
- Transaction Date: October 27, 2016.
- Price per Share: £16.365.
- Exchange: London Stock Exchange (XLON).
- ISIN: GB0009252882.